Synthetic microbial consortia based on quorum-sensing for disease therapy

Abstract

Synthetic microbial consortia (SyMCon), composed of different artificially engineered bacteria, offer a promising alternative to live biotherapeutic products for disease therapy. These microbial communities use a quorum sensing (QS) mechanism that allows for precise and low-interference communication. Compared to current therapy using only one engineered bacterium, they can reduce the metabolic load of one bacterium, thereby increase drug production, and respond to a wider variety of disease-related signals. This review summarizes recent developments and emphasizes the unique advantages of SyMCon, then proposes multiple perspectives of designs for therapeutic SyMCon. Although SyMCon possess advantages in colonization, responding to multiple environmental signals, and delivering high-yield drugs, future developments should focus on orthogonal QS systems, complex genetic circuits, and modular consortia. More complex consortia allow for better therapeutic functionality, and modular consortia allow for the rapid replacement of disease-specific components, which could unlock the potential of the next generation of personalized microbial therapy.

Keywords

Synthetic microbial consortia / Engineered bacteria / Quorum sensing / Disease treatment / Live biotherapeutic products

References

[1] Abisado RG, Benomar S, Klaus JR, Dandekar AA, Chandler JR. Bacterial quorum sensing and microbial community interactions. Mbio, 2018

[2] Aggarwal N, Kitano S, Puah GRY, Kittelmann S, Hwang IY, et al.. Microbiome and human health: current understanding, engineering, and enabling technologies. Chem Rev, 2023, 123: 31-72

[3] Alnahhas RN, Winkle JJ, Hirning AJ, Karamched B, Ott W, et al.. Spatiotemporal dynamics of synthetic microbial consortia in microfluidic devices. ACS Synth Biol, 2019, 8: 2051-2058

[4] Bai Y, Mansell TJ. Production and sensing of butyrate in a probiotic Escherichia coli strain. Int J Mol Sci, 2020

[5] Balagaddé FK, Song H, Ozaki J, Collins CH, Barnet M, et al.. A synthetic Escherichia coli predator-prey ecosystem. Mol Syst Biol, 2008, 4 187

[6] Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology, 2014, 146: 1547-1553

[7] Canale FP, Basso C, Antonini G, Perotti M, Li N, et al.. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature, 2021, 598: 662-666

[8] Chen Y, Kim JK, Hirning AJ, Josić K, Bennett MR. Emergent genetic oscillations in a synthetic microbial consortium. Science, 2015, 349: 986-989

[9] Chen JX, Steel H, Wu YH, Wang Y, Xu J, et al.. Development of aspirin-inducible biosensors in Escherichia coli and SimCells. Appl Environ Microbiol, 2019

[10] Chen XJ, Wang B, Thompson IP, Huang WE. Rational design and characterization of nitric oxide biosensors in E. coli Nissle 1917 and mini simcells. ACS Synth Biol, 2021, 10: 2566-2578

[11] Chen H, Lei P, Ji H, Yang Q, Peng B, et al.. Advances in Escherichia coli Nissle 1917 as a customizable drug delivery system for disease treatment and diagnosis strategies. Mater Today Bio, 2023, 18 100543

[12] Chen X, Gao M, Wang L, Qiang G, Wu Y, et al.. A synthetic microbial consortium protects against obesity by regulating vitamin B6 metabolism. Gut Microbes, 2024, 16: 2304901

[13] Chen Z, Yong T, Wei Z, Zhang X, Li X, et al.. Engineered probiotic-based personalized cancer vaccine potentiates antitumor immunity through initiating trained immunity. Adv Sci (Weinh), 2024, 11 e2305081

[14] Cheng AG, Ho PY, Aranda-Díaz A, Jain S, Yu FB, et al.. Design, construction, and in vivo augmentation of a complex gut microbiome. Cell, 2022, 185: 3617-3636.e3619

[15] Chowdhury S, Castro S, Coker C, Hinchliffe TE, Arpaia N, et al.. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat Med, 2019, 25: 1057-1063

[16] Collins SL, Stine JG, Bisanz JE, Okafor CD, Patterson AD. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol, 2023, 21: 236-247

[17] Cooper RM, Wright JA, Ng JQ, Goyne JM, Suzuki N, et al.. Engineered bacteria detect tumor DNA. Science, 2023, 381: 682-686

[18] Cui S, Lv X, Xu X, Chen T, Zhang H, et al.. Multilayer genetic circuits for dynamic regulation of metabolic pathways. ACS Synth Biol, 2021, 10: 1587-1597

[19] Dang Z, Gao M, Wang L, Wu J, Guo Y, et al.. Synthetic bacterial therapies for intestinal diseases based on quorum-sensing circuits. Biotechnol Adv, 2023, 65 108142

[20] Datla US, Mather WH, Chen S, Shoultz IW, Täuber UC, et al.. The spatiotemporal system dynamics of acquired resistance in an engineered microecology. Sci Rep, 2017, 7: 16071

[21] Diaz-Colunga J, Skwara A, Vila JCC, Bajic D, Sanchez A. Global epistasis and the emergence of function in microbial consortia. Cell, 2024, 187: 3108-3119.e3130

[22] Din MO, Danino T, Prindle A, Skalak M, Selimkhanov J, et al.. Synchronized cycles of bacterial lysis for in vivo delivery. Nature, 2016, 536: 81-85

[23] Escudero-Martinez C, Bulgarelli D. Engineering the crop microbiota through host genetics. Annu Rev Phytopathol, 2023, 61: 257-277

[24] Flores G, Pickard JM, Núñez G. Microbiota-mediated colonization resistance: mechanisms and regulation. Nat Rev Microbiol, 2023, 21: 347-360

[25] Gao H, Jiang W, Zhang W, Jiang M, Xin F. Customized spatial niches for synthetic microbial consortia. Trends Biotechnol, 2023, 41: 1463-1466

[26] Gao T, Niu L, Wu X, Dai D, Zhou Y, et al.. Sonogenetics-controlled synthetic designer cells for cancer therapy in tumor mouse models. Cell Rep Med, 2024, 5 101513

[27] Gao T, Li Y, Dai K, Meng F. Electric syntrophy-driven modulation of Fe(0)-dependent microbial denitrification. Water Res, 2025, 268 122722

[28] Goto Y, Iwata S, Miyahara M, Miyako E. Discovery of intratumoral oncolytic bacteria toward targeted anticancer theranostics. Adv Sci (Weinh), 2023, 10 e2301679

[29] Grandel NE, Reyes Gamas K, Bennett MR. Control of synthetic microbial consortia in time, space, and composition. Trends Microbiol, 2021, 29: 1095-1105

[30] Großkopf T, Soyer OS. Synthetic microbial communities. Curr Opin Microbiol, 2014, 18: 72-77

[31] Gu F, Jiang W, Kang F, Su T, Yang X, et al.. A synthetic population-level oscillator in non-microfluidic environments. Commun Biol, 2023, 6: 515

[32] Guo Y, Gao M, Wang L, Yuan H, Yin J, et al.. An engineered probiotic consortium based on quorum-sensing for colorectal cancer immunotherapy. Adv Sci (Weinh), 2025

[33] Gurbatri CR, Lia I, Vincent R, Coker C, Castro S, et al.. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med, 2020

[34] Gurbatri CR, Radford GA, Vrbanac L, Im J, Thomas EM, et al.. Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia. Nat Commun, 2024, 15 646

[35] Hitch TCA, Bosch J, Bolsega S, Deschamps C, Etienne-Mesmin L, et al.. Function-based selection of synthetic communities enables mechanistic microbiome studies. ISME J, 2025

[36] Isabella VM, Ha BN, Castillo MJ, Lubkowicz DJ, Rowe SE, et al.. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat Biotechnol, 2018, 36: 857-864

[37] Jayaprakash M, Vijaya Kumar D, Chakraborty G, Chakraborty A, Kumar V. Bacteria-mediated cancer therapy (BMCT): therapeutic applications, clinical insights, and the microbiome as an emerging hallmark of cancer. Biomed Pharmacother, 2025, 192 118559

[38] Jayedi A, Aletaha A, Zeraattalab-Motlagh S, Shahinfar H, Mohammadpour S, et al.. Comparative efficacy and safety of probiotics, prebiotics, and synbiotics for type 2 diabetes management: a systematic review and network meta-analysis. Diabetes Metab Syndr, 2024, 18 102923

[39] Jennings SAV, Clavel T. Synthetic communities of gut microbes for basic research and translational approaches in animal health and nutrition. Annu Rev Anim Biosci, 2024, 12: 283-300

[40] Jiang W, Yang X, Gu F, Li X, Wang S, et al.. Construction of synthetic microbial ecosystems and the regulation of population proportion. ACS Synth Biol, 2022, 11: 538-546

[41] Jiang Y, Wu R, Zhang W, Xin F, Jiang M. Construction of stable microbial consortia for effective biochemical synthesis. Trends Biotechnol, 2023, 41: 1430-1441

[42] Karkaria BD, Fedorec AJH, Barnes CP. Automated design of synthetic microbial communities. Nat Commun, 2021, 12: 672

[43] Kuhn T, Junier P, Bshary R, Terrettaz C, Gonzalez D, et al.. Nutrients and flow shape the cyclic dominance games between Escherichia coli strains. Philos Trans R Soc Lond B Biol Sci, 2023, 378 20210503

[44] Kumar N, Hitch TCA, Haller D, Lagkouvardos I, Clavel T. Mimic: a bioinformatic approach for generation of synthetic communities from metagenomes. Microb Biotechnol, 2021, 14: 1757-1770

[45] Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, et al.. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer, 2016, 114: 1352-1361

[46] Lee TA, Morlock J, Allan J, Steel H. Directing microbial co-culture composition using cybernetic control. Cell Rep Methods, 2025, 5 101009

[47] Leeuwen PT, Brul S, Zhang J, Wortel MT. Synthetic microbial communities (SynComs) of the human gut: design, assembly, and applications. FEMS Microbiol Rev, 2023

[48] Leser T, Baker A. Molecular mechanisms of Lacticaseibacillus rhamnosus, LGG(®) probiotic function. Microorganisms, 2024

[49] Leventhal DS, Sokolovska A, Li N, Plescia C, Kolodziej SA, et al.. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun, 2020, 11: 2739

[50] Li C, Han Y, Zou X, Zhang X, Ran Q, et al.. A systematic discussion and comparison of the construction methods of synthetic microbial community. Synth Syst Biotechnol, 2024, 9: 775-783

[51] Liao MJ, Din MO, Tsimring L, Hasty J. Rock-paper-scissors: engineered population dynamics increase genetic stability. Science, 2019, 365: 1045-1049

[52] Liao MJ, Miano A, Nguyen CB, Chao L, Hasty J. Survival of the weakest in non-transitive asymmetric interactions among strains of E. coli. Nat Commun, 2020, 11 6055

[53] Liao J, Pan H, Huang G, Gong H, Chen Z, et al.. T cell cascade regulation initiates systemic antitumor immunity through living drug factory of anti-PD-1/IL-12 engineered probiotics. Cell Rep, 2024, 43 114086

[54] Liu H, Fan K, Li H, Wang Q, Yang Y, et al.. Synthetic gene circuits enable Escherichia coli to use endogenous H₂S as a signaling molecule for quorum sensing. ACS Synth Biol, 2019, 8: 2113-2120

[55] Liu Q, Gai Y, Chen Y, Lan X, Jiang D. Escherichia coli Nissle 1917 as a novel microrobot for tumor-targeted imaging and therapy. Pharmaceutics, 2021

[56] Liu X, Liu Q, Sun S, Sun H, Wang Y, et al.. Exploring AI-2-mediated interspecies communications within rumen microbial communities. Microbiome, 2022, 10: 167

[57] Liu C, Wang J, Lei L, Li L, Yuan X. Gut microbiota therapy for chronic kidney disease. Front Immunol, 2025, 16: 1660226

[58] Lynch JP, González-Prieto C, Reeves AZ, Bae S, Powale U, et al.. Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut. Cell Host Microbe, 2023, 31: 634-649.e638

[59] Ma X, Yin J, Qiao L, Wan H, Liu X, et al.. A programmable targeted protein-degradation platform for versatile applications in mammalian cells and mice. Mol Cell, 2024, 84: 1585-1600.e1587

[60] Mao J, Zhang H, Chen Y, Wei L, Liu J, et al.. Relieving metabolic burden to improve robustness and bioproduction by industrial microorganisms. Biotechnol Adv, 2024, 74 108401

[61] McBride CD, Del Vecchio D. Predicting composition of genetic circuits with resource competition: demand and sensitivity. ACS Synth Biol, 2021, 10: 3330-3342

[62] McCarty NS, Ledesma-Amaro R. Synthetic biology tools to engineer microbial communities for biotechnology. Trends Biotechnol, 2019, 37: 181-197

[63] Mehlferber EC, Arnault G, Joshi B, Partida-Martinez LP, Patras KA, et al.. A cross-systems primer for synthetic microbial communities. Nat Microbiol, 2024, 9: 2765-2773

[64] Merk LN, Shur AS, Jena S, Munoz J, Brubaker DK, et al.. Diagnostic and therapeutic microbial circuit with application to intestinal inflammation. ACS Synth Biol, 2024, 13: 3885-3896

[65] Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, et al.. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol, 2014, 25: 1995-2001

[66] Moon TS, Lou C, Tamsir A, Stanton BC, Voigt CA. Genetic programs constructed from layered logic gates in single cells. Nature, 2012, 491: 249-253

[67] Mukherjee S, Bassler BL. Bacterial quorum sensing in complex and dynamically changing environments. Nat Rev Microbiol, 2019, 17: 371-382

[68] Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, et al.. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science, 2020, 368: 973-980

[69] Oliveira RA, Cabral V, Torcato I, Xavier KB. Deciphering the quorum-sensing lexicon of the gut microbiota. Cell Host Microbe, 2023, 31: 500-512

[70] Patra D, Dev G, Hand TW, Overacre-Delgoffe A. Friends close, enemies closer: the complex role of the microbiome in antitumor immunity. Curr Opin Immunol, 2025, 93 102537

[71] Paul P, Kaul R, Abdellatif B, Arabi M, Upadhyay R, et al.. The promising role of microbiome therapy on biomarkers of inflammation and oxidative stress in type 2 diabetes: a systematic and narrative review. Front Nutr, 2022, 9 906243

[72] Perez M, Ntemiri A, Tan H, Harris HMB, Roager HM, et al.. A synthetic consortium of 100 gut commensals modulates the composition and function in a colon model of the microbiome of elderly subjects. Gut Microbes, 2021, 13: 1-19

[73] Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM, et al.. Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli. Nature, 2020, 580: 269-273

[74] Puljiz Z, Kumric M, Vrdoljak J, Martinovic D, Ticinovic Kurir T, et al.. Obesity, gut microbiota, and metabolome: from pathophysiology to nutritional interventions. Nutrients, 2023

[75] Qian Y, Huang HH, Jiménez JI, Del Vecchio D. Resource competition shapes the response of genetic circuits. ACS Synth Biol, 2017, 6: 1263-1272

[76] Quinn-Bohmann N, Carr AV, Diener C, Gibbons SM. Moving from genome-scale to community-scale metabolic models for the human gut microbiome. Nat Microbiol, 2025, 10: 1055-1066

[77] Romero R, Zarzycka A, Preussner M, Fischer F, Hain T, et al.. Selected commensals educate the intestinal vascular and immune system for immunocompetence. Microbiome, 2022, 10: 158

[78] Roustapoor R, Abdi E, Khabbaz A, Abdi A. The metabolic and immunomodulatory functions of Bacteroides fragilis; a next-generation probiotic?. Med Microecol, 2025, 25 100137

[79] Sanchez A, Bajic D, Diaz-Colunga J, Skwara A, Vila JCC, et al.. The community-function landscape of microbial consortia. Cell Syst, 2023, 14: 122-134

[80] Sgobba E, Wendisch VF. Synthetic microbial consortia for small molecule production. Curr Opin Biotechnol, 2020, 62: 72-79

[81] Shan Y, Lee M, Chang EB. The gut microbiome and inflammatory bowel diseases. Annu Rev Med, 2022, 73: 455-468

[82] Shen Z, Gu L, Mao D, Chen M, Jin R. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis. World J Surg Oncol, 2019, 17: 4

[83] Shi Z, Li Z, Zhang M. Emerging roles of intratumor microbiota in cancer: tumorigenesis and management strategies. J Transl Med, 2024, 22: 837

[84] Shu X, Liu Y. Collaboration promotes stability: insights from SynComs study. Trends Microbiol, 2025

[85] Soma Y, Takahashi M, Fujiwara Y, Shinohara T, Izumi Y, et al.. Design of synthetic quorum sensing achieving induction timing-independent signal stabilization for dynamic metabolic engineering of E. coli. ACS Synth Biol, 2021, 10: 1384-1393

[86] Song H, Ding MZ, Jia XQ, Ma Q, Yuan YJ. Synthetic microbial consortia: from systematic analysis to construction and applications. Chem Soc Rev, 2014, 43: 6954-6981

[87] Sun Q, Ji YC, Ai Q, She X, Liu XC, et al.. Exogenous autoinducer-2 alleviates intestinal damage in necrotizing enterocolitis via PAR2/MMP3 signaling pathway. Int Immunopharmacol, 2024, 138 112567

[88] Tegegne HA, Savidge TC. Leveraging human microbiomes for disease prediction and treatment. Trends Pharmacol Sci, 2025, 46: 32-44

[89] Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol, 2020, 20: 40-54

[90] Waheed H, Xiao Y, Hashmi I, Zhou Y. The selective pressure of quorum quenching on microbial communities in membrane bioreactors. Chemosphere, 2020, 247 125953

[91] Wang M, Chen X, Ma Y, Tang YQ, Johnson DR, et al.. Type IV pilus shapes a 'bubble-burst' pattern opposing spatial intermixing of two interacting bacterial populations. Microbiol Spectr, 2022, 10 e0194421

[92] Wang L, Zhang X, Tang C, Li P, Zhu R, et al.. Engineering consortia by polymeric microbial swarmbots. Nat Commun, 2022, 13: 3879

[93] Wang T, Yin Q, Huang HY, Wang Z, Song H, et al.. Probiotic Escherichia coli Nissle 1917 propelled micro-robot with pH sensitivity for hypoxia targeted intestinal tumor therapy. Colloids Surf B Biointerfaces, 2023, 225 113277

[94] Wang X, Kang L, Kong D, Wu X, Zhou Y, et al.. A programmable protease-based protein secretion platform for therapeutic applications. Nat Chem Biol, 2024, 20: 432-442

[95] Wang Z, Peters BA, Yu B, Grove ML, Wang T, et al.. Gut microbiota and blood metabolites related to fiber intake and type 2 diabetes. Circ Res, 2024, 134: 842-854

[96] Wang S, Mu L, Yu C, He Y, Hu X, et al.. Microbial collaborations and conflicts: unraveling interactions in the gut ecosystem. Gut Microbes, 2024, 16: 2296603

[97] Wang Z, Wang S, He Q, Yang X, Zhao B, et al.. Ecological design of high-performance synthetic microbial communities: from theoretical foundations to functional optimization. ISME Commun, 2025, 5 ycaf133

[98] Wienhausen G, Moraru C, Bruns S, Tran DQ, Sultana S, et al.. Ligand cross-feeding resolves bacterial vitamin B(12) auxotrophies. Nature, 2024, 629: 886-892

[99] Woo SG, Moon SJ, Kim SK, Kim TH, Lim HS, et al.. A designed whole-cell biosensor for live diagnosis of gut inflammation through nitrate sensing. Biosens Bioelectron, 2020, 168 112523

[100] Wu S, Xue Y, Yang S, Xu C, Liu C, et al.. Combinational quorum sensing devices for dynamic control in cross-feeding cocultivation. Metab Eng, 2021, 67: 186-197

[101] Wu S, Zhou Y, Dai L, Yang A, Qiao J. Assembly of functional microbial ecosystems: from molecular circuits to communities. FEMS Microbiol Rev, 2024

[102] Yan X, Liu XY, Zhang D, Zhang YD, Li ZH, et al.. Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis. Cell Mol Immunol, 2021, 18: 2344-2357

[103] Yang G, Wei J, Liu P, Zhang Q, Tian Y, et al.. Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism, 2021, 117 154712

[104] Yang Y, Yu P, Huang Y, Zhang W, Nie Y, et al.. Metabolic engineering of Lactobacilli spp. for disease treatment. Microb Cell Fact, 2025, 24 53

[105] Yang Q, Xiang W, Khan A, Salama ES, Kulshreshtha S, et al.. Programmable probiotic consortium employ an oleic acid-inducible system to sense and degrade cholesterol in high-fat diet mice. Gut Microbes, 2025, 17: 2531198

[106] Zahir A, Okorie PA, Nwobasi VN, David EI, Nwankwegu RO, et al.. Harnessing microbial signal transduction systems in natural and synthetic consortia for biotechnological applications. Biotechnol Appl Biochem, 2024

[107] Zeng X, Zou Y, Zheng J, Qiu S, Liu L, et al.. Quorum sensing-mediated microbial interactions: mechanisms, applications, challenges and perspectives. Microbiol Res, 2023, 273 127414

[108] Zhang Q, Lyu S. iTRAQ-based proteomics analysis of Bacillus pumilus responses to acid stress and quorum sensing in a vitamin C fermentation system. Front Microbiol, 2023, 14: 1131000

[109] Zhao J, Sun H, Wang G, Wang Q, Wang Y, et al.. Engineering chimeric chemoreceptors and two-component systems for orthogonal and leakless biosensing of extracellular γ-aminobutyric acid. J Agric Food Chem, 2024, 72: 14216-14228

[110] Zhou T, Wu J, Tang H, Liu D, Jeon BH, et al.. Enhancing tumor-specific recognition of programmable synthetic bacterial consortium for precision therapy of colorectal cancer. NPJ Biofilms Microbiomes, 2024, 10: 6

[111] Zhou J, Zhao W, Wu M, Wu J, Zhu J, et al.. Quorum sensing regulates the efficiency of a microcystin-degrading microbial consortium. J Hazard Mater, 2025, 494 138479

[112] Zhu J, Ke Y, Liu Q, Yang J, Liu F, et al.. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy. Nat Commun, 2022, 13: 7466

[113] Zou ZP, Du Y, Fang TT, Zhou Y, Ye BC. Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in mice. Cell Host Microbe, 2023, 31: 199-212.e195

[114] Zygulska AL, Pierzchalski P. Novel diagnostic biomarkers in colorectal cancer. Int J Mol Sci, 2022

Funding

“Pioneer” and “Leading Goose” R&D Program of Zhejiang(2024C03013)

Key Technologies Research and Development Program(2024YFA0918500)

Fundamental Research Funds for the Central Universities(226-2025-00198)

National Key Research and Development Program of China(2022YFA0913000)

National Natural Science Foundation of China(22378351)

RIGHTS & PERMISSIONS

The Author(s)